What Is the Dapivirine Ring?

Size: px
Start display at page:

Download "What Is the Dapivirine Ring?"

Transcription

1 What Is the Dapivirine Ring? Dr. Zeda Rosenberg, CEO Beyond Phase III: 2014 Civil Society Consultation

2 What Are Microbicides? Products being developed to help prevent sexually transmitted HIV infection Most contain ARVs, already used successfully to treat HIV Could come in many forms to meet women s varying needs: Vaginal gel applicator Long-acting vaginal ring Vaginal tablet, soft gel, film Ideally safe, effective, low cost, user-friendly 2

3 Who Is IPM? Nonprofit organization working to protect women s sexual and reproductive health Developing products like the dapivirine ring to reduce the risk of HIV transmission to women safely and effectively Funded by governments and foundations Work with local research centres and trial networks like MTN to conduct clinical trials of our products Offices in South Africa and US 3

4 Microbicide Vaginal Rings Long-acting: monthly or longer o Could potentially improve adherence o Better adherence better effectiveness Easy to use, comfortable o Flexible ring, can be self-inserted o Rarely felt by women or male partners o Little or no impact on sexual activity Suitable for developing world o Relatively low manufacturing cost o Good safety and acceptability data Potential for contraceptive/arv combinations Important potential new option for women 4

5 What is Dapivirine? Highly potent ARV (NNRTI) Developed by Janssen o Evaluated in preclinical and clinical studies as oral therapeutic Licensed to IPM in 2004 o Royalty-free license to develop as topical microbicide for HIV prevention in developing countries Acts inside cells in the vagina to block the ability of HIV to multiply 5

6 Dapivirine Vaginal Ring Off-white flexible silicone ring Made by mixing dapivirine into liquid silicone The mixture is put into a ring mold and heated The solid ring can slowly release drug into vaginal tissue Now in late-stage clinical trials: The Ring Study and ASPIRE 6

7 7 How the Dapivirine Ring is Used

8 Prior Research Vaginal rings used safely and effectively for other medical uses in Europe and US for almost 20 years Dapivirine found to be safe and welltolerated in over 20 clinical trials by IPM and partners since IPM clinical trials to date show dapivirine ring is safe and welltolerated (6 clinical trials ongoing) IPM clinical trials also show steady drug release and low systemic absorption 8

9 What we know about dapivirine ring acceptability Among women Very comfortable Not felt during daily activities Willing to use if effective Among men Most did not feel during sex No impact on sexual pleasure and no side effects Most favorable characteristics to women Potential for HIV prevention Does not alter sexual experience Worn every day Involving male partners Important partner accepts ring 9

10 10 Dapivirine Ring Licensure Program

11 Dapivirine Ring Licensure Program IPM 027 Long-term safety and efficacy 1950 participants, ongoing ( ) in Africa MTN-020 Additional safety and PK clinical trials Safety and effectiveness 2629 participants enrolled, ongoing ( ) in Africa Drug-drug interactions Condom functionality (male and female) Safety in adolescents (15-17 years) and post-menopausal women (>45 years) Effect of menses/tampon use 11

12 Why Two Parallel Phase III Trials? Regulatory approval usually requires results from at least two Phase III clinical trials One Phase III trial can take 4-6 years, from design to data analysis Running two clinical trials in parallel saves time enabling rapid regulatory submission if the dapivirine ring shows safety and efficacy 12

13 Thank you! Questions? A microbicide could mean the difference between life and death for millions of women. Let us do everything in our power to accelerate its development. Mrs. Graça Machel 13

International Partnership for Microbicides

International Partnership for Microbicides International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March

More information

From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager

From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager MTN Regional Meeting Plenary Meeting 19 September 2017 Overview From Ring to DREAM Women s Vulnerability to HIV Women Need Multiple Options

More information

QUESTIONS AND ANSWERS

QUESTIONS AND ANSWERS CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use The Big Picture 1. What is the aim of

More information

QUESTIONS AND ANSWERS

QUESTIONS AND ANSWERS CONTACTS: Clare Collins Lisa Rossi +1-412-641-7299 +1-412-641-8940 +1-412-770-8643 (mobile) +1-412-916-3315 (mobile) collcx@upmc.edu rossil@upmc.edu QUESTIONS AND ANSWERS MTN-016: HIV Prevention Agent

More information

QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use

QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use I. ASPIRE and The Ring Study: The Basics

More information

International Partnership for Microbicides

International Partnership for Microbicides International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15

More information

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled

More information

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety

More information

Understanding the Results of VOICE

Understanding the Results of VOICE CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the

More information

International Partnership for Microbicides. Phase III Clinical Trial Design Institute of Medicine February 6, 2007

International Partnership for Microbicides. Phase III Clinical Trial Design Institute of Medicine February 6, 2007 International Partnership for Microbicides Phase III Clinical Trial Design Institute of Medicine February 6, 2007 IPM Product Development Strategy ARV-based gels, intravaginal rings, tablets, etc. Once

More information

International Partnership for Microbicides

International Partnership for Microbicides International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV

More information

Novel HIV Prevention Methods for Women

Novel HIV Prevention Methods for Women Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health

More information

The Big Picture: The current and evolving HIV prevention landscape

The Big Picture: The current and evolving HIV prevention landscape The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine

More information

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill

More information

ASPIRE Overview Where we are today

ASPIRE Overview Where we are today ASPIRE Overview Where we are today Flavia Matovu Kiweewa, MBChB, Msc. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration Beyond Phase III: Seeking civil society perspectives on

More information

The Open Label Trial Past and Present

The Open Label Trial Past and Present The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in

More information

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5

More information

The Open Label Trial Past and Present

The Open Label Trial Past and Present The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention

More information

The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018

The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018 The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts

More information

International Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard

International Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard International Partnership for Microbicides Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard Dr. Zeda Rosenberg February 20, 2007 The Face of HIV Globally Increasingly

More information

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

Informed Consent Flipchart. Version 1.0, 30 Jan 2018 Informed Consent Flipchart Version 1.0, 30 Jan 2018 Knowledge is Power Did you know? Across the world, young women are at high risk of getting HIV. In Africa, more than half of people living with HIV are

More information

What s in the Biomedical Prevention Pipeline

What s in the Biomedical Prevention Pipeline What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure

More information

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

MTN 034/IPM 045: REACH Rings and PrEP in Young Women MTN 034/IPM 045: REACH Rings and PrEP in Young Women Lulu Nair CRS Leader: Emavundleni -Cape Town On behalf of MTN 034 protocol team MTN Annual Meeting: 2017 Bethesda North Marriott Hotel and Conference

More information

What We Will Learn From the REACH Study

What We Will Learn From the REACH Study What We Will Learn From the REACH Study Lulu Nair (MBChB, MPH) MTN 034/IPM 045 Protocol Chair On behalf of protocol team 19 Sep 2017 MTN Regional Meeting 2017 Cape Town Overview Importance / Value of REACH

More information

Danish Organisation Strategy. for. International Partnership for Microbicides (IPM)

Danish Organisation Strategy. for. International Partnership for Microbicides (IPM) Danish Organisation Strategy for International Partnership for Microbicides (IPM) 2014-2018 August 2014 1. Objective 1.1. Objective of strategy This strategy for the cooperation between Denmark and the

More information

Understanding the results of CAPRISA 004

Understanding the results of CAPRISA 004 A Cascade of Hope and Questions Volume 2 Understanding the results of CAPRISA 004 Key messages CAPRISA 004 provides the first proof of concept that a microbicide (1% tenofovir gel) can reduce women s risk

More information

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP

Where We Have Been and Where We are Going. Ian McGowan MD PhD FRCP Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve

More information

The Big Picture: The current and evolving HIV prevention landscape

The Big Picture: The current and evolving HIV prevention landscape The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV

More information

Welcome and State of the Network. Cape Town, South Africa 27 th September 2016

Welcome and State of the Network. Cape Town, South Africa 27 th September 2016 Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living

More information

TRAINING PROGRAM CUPID FEMALE CONDOM

TRAINING PROGRAM CUPID FEMALE CONDOM CUPID LIMITED, INDIA WE HELP THE WORLD PLAY SAFE... Manufacturer and Supplier of Male Condoms, Female Condoms & Water based Lubricants. TRAINING PROGRAM CUPID FEMALE CONDOM Website:- http://www.cupidlimited.com

More information

Update on ARV based PrEP

Update on ARV based PrEP Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV

More information

Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago

Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago Direct from Delhi: Microbicides2008 Comes to Sweet Home Chicago Microbicide Pipeline Update Latifa Boyce Alliance for Microbicide Development Outline Past: Where we ve been Present: Where we are Future:

More information

Biomedical Prevention Update Thomas C. Quinn, M.D.

Biomedical Prevention Update Thomas C. Quinn, M.D. Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global

More information

Behavioral Research in the Microbicide Trials Network

Behavioral Research in the Microbicide Trials Network Behavioral Research in the Microbicide Trials Network HANC Behavioral Sciences Working Group Symposium Miami June 8, 2014 Ariane van der Straten, PhD, MPH Member, MTN Behavioral Research Working Group

More information

Update on Antiretroviral-Based HIV Prevention

Update on Antiretroviral-Based HIV Prevention Update on Antiretroviral-Based HIV Prevention Prof. Janneke van de Wijgert University of Liverpool, Institute of Infection and Global Health Click to edit Master subtitle style 12th European Meeting on

More information

Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health

Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health Session Objectives This session is designed to help you: Define multipurpose prevention technologies (MPTs) Describe 3 benefits

More information

Next Generation PrEP? Injectable & Implantable ARVs

Next Generation PrEP? Injectable & Implantable ARVs Next Generation PrEP? Injectable & Implantable ARVs Craig W. Hendrix, MD Wellcome Professor & Director, Clinical Pharmacology Johns Hopkins University Objectives Describe alternative formulations to improve

More information

Where are we going after effectiveness studies?

Where are we going after effectiveness studies? Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years

More information

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global

More information

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics

More information

MTN 2011 Annual Meeting Arlington, VA. The Microbicide Pipeline: A Critical Review. J. Romano March 29, 2011

MTN 2011 Annual Meeting Arlington, VA. The Microbicide Pipeline: A Critical Review. J. Romano March 29, 2011 MTN 2011 Annual Meeting Arlington, VA The Microbicide Pipeline: A Critical Review J. Romano March 29, 2011 What is the microbicide pipeline and how is it prioritized and progressed? The Microbicide Pipeline?

More information

October 2010 INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

October 2010 INTERNATIONAL PARTNERSHIP FOR MICROBICIDES October 2010 G I V P I N G O W O W M E N R O V E R A I D S M I C R O B I C I D E S INTERNATIONAL PARTNERSHIP FOR MICROBICIDES remains one of the greatest burdens to the future health and well-being of

More information

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure

More information

Overview of ARV-based prevention trials

Overview of ARV-based prevention trials Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical

More information

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with

More information

17. Preventing pregnancy

17. Preventing pregnancy 17. Preventing pregnancy Objectives By the end of this session, group members will be able to: Define contraception. List ways young people can prevent pregnancy. Background notes What is contraception?

More information

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA The Promise of HIV Prevention in Pregnancy Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA Outline Pregnancy/Lactation Brief background Where we were Where we are now Where we are

More information

DAPIVIRINE RING THE CASE FOR ACTION RESEARCH BY

DAPIVIRINE RING THE CASE FOR ACTION RESEARCH BY DAPIVIRINE RING THE CASE FOR ACTION RESEARCH BY About the Dapivirine Ring The monthly dapivirine ring is the first discrete, long-acting, HIV-prevention product designed specifically for women. Developed

More information

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,

More information

Advances in Topical Protection Against HIV-1 Infection. Ross D. Cranston MB ChB MD FRCP Fundació Lluita contra la SIDA Barcelona

Advances in Topical Protection Against HIV-1 Infection. Ross D. Cranston MB ChB MD FRCP Fundació Lluita contra la SIDA Barcelona Advances in Topical Protection Against HIV-1 Infection Ross D. Cranston MB ChB MD FRCP Fundació Lluita contra la SIDA Barcelona Summary Microbicide background The concept and potential acceptability Vaginal

More information

Doing studies of ARV based

Doing studies of ARV based Doing studies of ARV based microbicides what s s different, what s s the same? Gonasagrie Nair, MBChB, DTM&H, MPH CAPRISA ethekwini Site Project Director & IoR VOICE Trial OVERVIEW Brief historical overview

More information

Oral Versus Injectable Delivery, Impact on Adherence/Tolerability

Oral Versus Injectable Delivery, Impact on Adherence/Tolerability Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

ARVs for prevention in at-risk populations: Microbicides

ARVs for prevention in at-risk populations: Microbicides ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):

More information

MTN 2018 State of the Network

MTN 2018 State of the Network MTN 2018 State of the Network Jared Baeten MD PhD Co-PI, Microbicides Trials Network Vice Chair, Department of Global Health Professor, Departments of Global Health, Medicine, and Epidemiology Director,

More information

An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria

An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies

More information

Options in HIV Prevention A Participant-Centered Counseling Approach

Options in HIV Prevention A Participant-Centered Counseling Approach Options in HIV Prevention A Participant-Centered Counseling Approach Options Counseling Flipchart, Version 3.0, 10 Oct 2017 Enrollment Visit Welcome and thank you! 3 HOPE Adherence Counseling CHOICE: Helping

More information

PrEP in Scotland. PrEP. in Scotland. PrEP. PrEP. PrEP. PrEP is a combination pill that prevents HIV.

PrEP in Scotland. PrEP. in Scotland. PrEP. PrEP. PrEP. PrEP is a combination pill that prevents HIV. PrEP in Scotland PrEP PrEP PrEP PrEP is a combination pill that prevents HIV. 1 Contents Introduction 3 What is PrEP 3 Who should take PrEP 4 Getting PrEP in Scotland 5 Side effects and interactions with

More information

CHARMed An Update on the Combination HIV Antiretroviral Rectal Microbicide Program

CHARMed An Update on the Combination HIV Antiretroviral Rectal Microbicide Program CHARMed An Update on the Combination HIV Antiretroviral Rectal Microbicide Program Ian McGowan MD PhD FRCP Magee Womens Research Institute University of Pittsburgh, USA Overview Rectal microbicide development

More information

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc

Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health

More information

M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010

M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 HIV Prevention Research: The Global Picture Presented at: M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 Salim S. Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director:

More information

PrEP: Community Perspectives Rebekah Webb, EATG. 14 th European Meeting on HIV & Hepatitis 2016 Rome, 25 th May 2016

PrEP: Community Perspectives Rebekah Webb, EATG. 14 th European Meeting on HIV & Hepatitis 2016 Rome, 25 th May 2016 PrEP: Community Perspectives Rebekah Webb, EATG 14 th European Meeting on HIV & Hepatitis 2016 Rome, 25 th May 2016 Different kinds of PrEP Oral PrEP (TDF/FTC; TDF/3TC) Injectable PrEP (cabotegravir/rilpivirine)

More information

HIV AND AIDS FACT SHEETS

HIV AND AIDS FACT SHEETS The Human Immunodeficiency Virus (HIV) has been one of the most devastating new diseases to emerge over the course of the past century. Even though HIV may not always be in the headlines now, it is still

More information

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Overview A brief history of oral/la PrEP research Integration

More information

CONTINUED LESSONS FROM VOICE

CONTINUED LESSONS FROM VOICE CONTINUED LESSONS FROM VOICE Z Mike Chirenje MD FRCOG University of Zimbabwe, Dept. of Obstetrics and Gynaecology, College of Health Science, Harare, Zimbabwe VOICE Study Summary VOICE was a RCT (N=5029)

More information

Birth Control Options Chart

Birth Control Options Chart Hormonal Methods Birth control pills also known as mini-pills 91-99% A daily pill containing hormones that stops you from ovulating. There are combination estrogen or progestin-only (mini-pill) options.

More information

Approaches to Understanding the End User for Microbicide Introduction. Creating Desire for Microbicides Meeting May 2014

Approaches to Understanding the End User for Microbicide Introduction. Creating Desire for Microbicides Meeting May 2014 Approaches to Understanding the End User for Microbicide Introduction Creating Desire for Microbicides Meeting May 2014 Bottleneck analysis: assess introduction challenges, even at early stages of product

More information

100% Highly effective No cost No side effects

100% Highly effective No cost No side effects effective? Advantages Disadvantages How do I get Cost Abstinence For some it can mean no sexual contact. For others it is no sexual intercourse or vaginal penetration. A permanent surgical procedure available

More information

CROI 2016 Update NEAETC, March 21, Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School

CROI 2016 Update NEAETC, March 21, Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School CROI 2016 Update NEAETC, March 21, 2016 Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School CROI 2016 Update NEAETC, March 21, 2016 UNITED STATES EPIDEMIOLOGY Estimating the lifetime risk

More information

Section 11. Counseling Procedures

Section 11. Counseling Procedures Section 11. Counseling Procedures 11.1 HIV Counseling... 11-1 11.2 Protocol Counseling... 11-2 11.2.1 Contraception Counseling... 11-3 11.2.2 Protocol Adherence Counseling... 11-4 11.2.3 Product Use Counseling...

More information

Discover the birth control you ve been looking for. Highly reliable. Virtually hassle-free. Totally hormone-free.

Discover the birth control you ve been looking for. Highly reliable. Virtually hassle-free. Totally hormone-free. Discover the birth control you ve been looking for Highly reliable. Virtually hassle-free. Totally hormone-free. Over 70 million women worldwide use a nonhormonal IUC like ParaGard. Millions of women with

More information

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated

More information

Translating the Science to End New HIV Infections in Kenya

Translating the Science to End New HIV Infections in Kenya Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of

More information

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings. The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings Counseling Cards Checklist to be reasonably sure a woman is not pregnant

More information

Gel Product Attribute Study

Gel Product Attribute Study Gel Product Attribute Study Results Report International Partnership for Microbicides 8401 Colesville Road, Suite 200 Silver Spring, Maryland 20910 www.ipm-microbicides.org August 2007 1 INTERNATIONAL

More information

The MTN Pipeline. Ian McGowan MD PhD FRCP Cape Town, South Africa MTN Regional Meeting October, 2009

The MTN Pipeline. Ian McGowan MD PhD FRCP Cape Town, South Africa MTN Regional Meeting October, 2009 The MTN Pipeline Ian McGowan MD PhD FRCP Cape Town, South Africa MTN Regional Meeting October, 2009 Overview Microbicide development The microbicide pipeline? Generic IPM CONRAD Other The current MTN portfolio

More information

United Nations General Assembly June 8, 2011

United Nations General Assembly June 8, 2011 Remarks by Dr. Mathilde Krim United Nations General Assembly June 8, 2011 I am Mathilde Krim, the Founding Chairman of amfar, The Foundation for AIDS Research. This is a not-for-profit foundation based

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness

More information

Progress against the HIV Epidemic: is the end in sight?

Progress against the HIV Epidemic: is the end in sight? Progress against the HIV Epidemic: is the end in sight? Christine Hughes, BscPharm, PharmD, FCSHP Professor, Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Clinical Pharmacist, Northern

More information

HIV Prevention Tools: What does the Community Say?

HIV Prevention Tools: What does the Community Say? HIV Prevention Tools: What does the Community Say? Brenda Gati Mirembe, MBChB, MSc Epi Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda MTN Regional Meeting, Cape Town,

More information

Section 10 Counseling Considerations

Section 10 Counseling Considerations Section 10 Counseling Considerations 10.1 HIV Pre- /Post-Test Counseling... 10-1 10.2 HIV/STI Risk Reduction Counseling... 10-2 10.3 Contraceptive Counseling... 10-3 10.4 Product Use Instructions... 10-4

More information

Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities?

Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities? Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities? Shelley Lees London School of Hygiene and Tropical Medicine biomedical technology

More information

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants. Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose

More information

SYNDROMIC CASE MANAGEMENT OF STD

SYNDROMIC CASE MANAGEMENT OF STD SYNDROMIC CASE MANAGEMENT OF STD Sexually Transmitted Diseases A Guide for Decision-makers, Health Care Workers, and Communicators WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC MANILA

More information

Program to control HIV/AIDS

Program to control HIV/AIDS 90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,

More information

The Prevention Landscape for Women: Yesterday, Today and Tomorrow. Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018

The Prevention Landscape for Women: Yesterday, Today and Tomorrow. Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018 The Prevention Landscape for Women: Yesterday, Today and Tomorrow Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018 Despite global progress in the last decade, women still bear a

More information

Anticipating ethical concerns during disaster research: perspectives from South Africa

Anticipating ethical concerns during disaster research: perspectives from South Africa Anticipating ethical concerns during disaster research: perspectives from South Africa Prof Keymanthri Moodley Bioethics Unit Tygerberg division Centre For Applied Ethics & Faculty of Health Sciences University

More information

MATES - Conform. MATES - King Size

MATES - Conform. MATES - King Size MATES - Natural MATES - Conform MATES - Ribbed Mates Natural Condoms are a regular sized condom which has a unique flared shape, making them slightly larger at the head for greater comfort. MATES - Original

More information

Understanding the Impact of an HIV Intervention Package for Adolescents

Understanding the Impact of an HIV Intervention Package for Adolescents Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1 Contents Introduction Literature Review

More information

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

On the Horizon for Consideration: Biomedical Advances in HIV Prevention On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council

More information

A Field on the Verge of Change

A Field on the Verge of Change RESEAR CH AND REALITY 9 A Field on the Verge of Change What it will take to find new prevention options for women at a unique intersection of research goals and reality. Unlike vaccine studies, which administer

More information

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory

More information

Injectable Antiretrovirals The Promise and the Peril. Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015

Injectable Antiretrovirals The Promise and the Peril. Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015 Injectable Antiretrovirals The Promise and the Peril Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015 The Promise Long Acting Formulations Have been used to improve

More information

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the

More information

The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016

The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016 The Kisumu Clinical Research Site Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016 Overview History of the Kisumu CRS Communities Served by the Kisumu CRS Completed Studies / Clinical

More information

Sexual Health. Spring 2017

Sexual Health. Spring 2017 Sexual Health Spring 2017 Understanding Sexual Health Sexual health is the ability to embrace and enjoy our sexuality throughout our lives. It is an important part of our physical and emotional health.

More information

Power Point Use in EBPs. CAPP & PREP Learning Community May 15, 2018

Power Point Use in EBPs. CAPP & PREP Learning Community May 15, 2018 Power Point Use in EBPs CAPP & PREP Learning Community May 15, 2018 Objectives Best practices for power point use Why use power point for EBP delivery Examples: the Good, the Bad and the Ugly Recommendations

More information

TasP - Individual versus Public Health Benefit versus Both.

TasP - Individual versus Public Health Benefit versus Both. Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We

More information

Integration of Behavioral Science in the MTN Where We've Been and Where We're Going. Pamina M. Gorbach MTN Behavioral Research Working Group

Integration of Behavioral Science in the MTN Where We've Been and Where We're Going. Pamina M. Gorbach MTN Behavioral Research Working Group Integration of Behavioral Science in the MTN Where We've Been and Where We're Going Pamina M. Gorbach MTN Behavioral Research Working Group Outline BRWG overview Data collection technologies Challenges

More information